Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd (NY: CANF )

2.380 USD -0.030 (-1.24%)
Official Closing Price Updated: 8:00 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Can-Fite Biopharma Ltd

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies 
From Business Wire News Releases
Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update 
From Business Wire News Releases
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® 
From Business Wire News Releases
Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma?
InvestorsObserver issues critical PriceWatch Alerts for NEOS, OCG, SINO, BAC, and CANF. 
From PR Newswire
Thinking about buying stock in Can Fite Biopharma, Aytu Bioscience, Hall of Fame Resort & Entertainment, Brickell Biotech, or Infinity Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for CANF, AYTU, HOFV, BBI, and INFI. 
From PR Newswire
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model. Issued Patents in major markets. 
From Business Wire News Releases
Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?
InvestorsObserver issues critical PriceWatch Alerts for CANF, ZOM, AMC, SVRA, and SSY. 
From PR Newswire
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma 
From Business Wire News Releases
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol 
From Business Wire News Releases
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI. 
From PR Newswire
New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech?
InvestorsObserver issues critical PriceWatch Alerts for CANF, CLSN, MARK, PSTV, and SNES. 
From PR Newswire
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies 
From Business Wire News Releases
Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers 
From Business Wire News Releases
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases
Can-Fite Reports on Progress With Its Namodenoson NASH Program
Can-Fite Reports on Progress with its Namodenoson NASH Program 
From Business Wire News Releases
Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020
Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 
From Business Wire News Releases
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update 
From Business Wire News Releases
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD) 
From Business Wire News Releases
Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET
Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET 
From Business Wire News Releases
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference 
From Business Wire News Releases
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 
From Business Wire News Releases
Thinking about buying stock in OraSure Technologies, AMC Entertainment, Can Fite Biopharma, American Airlines, or Canopy Growth Corp?
InvestorsObserver issues critical PriceWatch Alerts for OSUR, AMC, CANF, AAL, and CGC. 
From PR Newswire
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 
From Business Wire News Releases
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases
Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference
Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases 
From Business Wire News Releases
Can-Fite to Participate in Two BioPharma Partnering Conferences
Can-Fite to Participate in Two BioPharma Partnering Conferences 
From Business Wire News Releases
Thinking about buying stock in Can Fite Biopharma, Inovio Pharmaceuticals, Penn National Gaming, Delta Air Lines, or Advanced Micro Devices?
InvestorsObserver issues critical PriceWatch Alerts for CANF, INO, PENN, DAL, and AMD. 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.